drugset / Trial / NCT01561430
Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease
RandomizedParallel-groupTriple-blindBasic science
Summary
The purpose of this Phase 1/Phase 2 study is to evaluate how the body handles the drug and the drug's effect on the body of participants with mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or mild AD and who test positive for amyloid plaque.
Timeline
- Start
- 2012-03
- Primary completion
- 2013-08
- Completion
- 2013-08
Outcome
Outcome not reported
Stopped: “Study terminated due to abnormal liver biochemical tests in some participants.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY2886721 | Small molecule | 15 mg | Oral |
| Subject | LY2886721 | Small molecule | 35 mg | Oral |
| Subject | LY2886721 | Small molecule | 70 mg | Oral |